Studies have shown that active fund managers routinely underperform the S&P500 index*​

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)

ARWR Stock Predictions and Ratings

WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-33.30%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
24.20%

ARWR Stock Analysis

ARWR PE Ratio:

ARWR PEG Ratio: Not Available

ARWR Forward EPS Growth (12 month): 0.00%

ARWR PS Ratio: 16.4

ARWR PSG Ratio: -0.6

ARWR Forward Revenue Growth (12 month): -26.10%

ARWR Articles

No data was found